Organisation paid for research Program year 2025 Source: CMS Open Payments

Vilo Research Group Inc

Neither a doctor nor a teaching hospital

Research payments

$1,671,106

808 payments

Through program year 2025, Vilo Research Group Inc is reported as receiving $1,671,106 in research payments, across 808 payments.

By program year

6 rows

Year	Kind	Amount	Payments
2025	Research	$88,572	35
2024	Research	$337,429	79
2023	Research	$290,358	256
2022	Research	$394,299	268
2021	Research	$128,789	61
2020	Research	$431,660	109

Breakdown

Who paid Research payments · program years 2020–2025

AbbVie, Inc. $1,050,672 311 payments
Moderna TX, Inc. $280,985 185 payments
Genentech, Inc. $220,786 128 payments
Adamis Pharmaceuticals Corporation $89,660 175 payments
Novartis Pharmaceuticals Corporation $18,246 1 payment
CapsoVision, Inc. $9,358 7 payments
Ionis Pharmaceuticals, Inc. $1,400 1 payment

Studies the money was for Research payments · program years 2020–2025

A Study to Assess the Efficacy and Safety of Risankizumab in Participants With Ulcerative Colitis $280,246 64 payments
A Phase 3, Randomized, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1647 Cytomegalovirus (CMV) Vaccine in Healthy Participants 16 to 40 Years of Age $261,117 172 payments
Transmission Study Household $220,786 128 payments
M16-066 $104,883 23 payments
Study to Evaluate the Effects of Tempol (MBM-02) in COVID-19 Patients $89,660 175 payments
M14-675 $79,977 14 payments
M16-067 $79,497 25 payments
A Study to Evaluate the Long-Term Safety and Efficacy of Upadacitinib (ABT-494) in Participants With Ulcerative Colitis (UC) $78,908 28 payments
A Multicenter, Randomized, Double-Blind, Placebo Controlled 52-Week Maintenance and an Open-Label Extension Study of the Efficacy and Safety of Risankizumab in Subjects with Ulcerative Colitis $46,027 21 payments
A Study of the Efficacy and Safety of Risankizumab in Participants With Crohn Disease $44,809 12 payments

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.